Winter 2012 In This Issue: American Society of Hematology (ASH), American Society for Therapeutic Radiation Onocology (ASTRO), San Antonio Breast Cancer Symposium (SABCS), Radiological Society of North America (RSNA), International Society of Pediatric Oncology (SIOP), Society for Neuro Onocology (SNO) and Others Cooperative Group Abstracts: Breast Cancer CNS Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Head and Neck Cancer Hematological Cancer Kidney Cancer Leukemia, Myelodysplasia, and Transplantation Lung Cancer Lymphoma and Plasma Cell Disorders Melanoma/Skin Cancers Sarcoma/Bone and Soft Tissue Cancers Other Cancer NCI/CTEP Abstracts & Activities: DCTD/DCP Abstracts DCTD and DCP Activities The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention. Research Highlights in this Issue: POG-9906 : A research team from the Children’s Oncology Group ALL Committee, working with collaborators at St. Jude Children’s Research Hospital and the British Columbia Cancer Agency, identified therapeutically targetable novel chromosomal rearrangements and sequence mutations in a subset of patients with high-risk B- precursor ALL. This patient subset was defined by a gene expression profile similar to BCR-ABL1-positive ALL (Ph-like ALL) and showed an increased risk for treatment failure compared to other patients designated as high-risk based on standard clinical factors. Each of the Ph-like ALL cases had genomic alterations resulting in dysregulation of cytokine receptor and kinase signaling. Many of these genomic alterations are targetable with FDA-approved agents (e.g., translocations involving kinases PDGFRB, JAK2, and ABL), providing a clear pathway for clinical translation and for improving outcome for this subset of children with ALL and high risk for treatment failure. The research is a component of the NCI Childhood Cancer TARGET Initiative. RTOG-0525 : Molecular classification of cancers is beginning to have impact on the clinical trial designs as demonstrated by the article highlighted in this issue. Using data from RTOG 0525, a large phase 3 clinical trial that enrolled over 700 patients with glioblastoma multiforme (GBM), the investigators were able to validate a combined molecular-clinical classifier. Prognostic classification of GBM has been clinical thus far; one example being Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) based classes. Using the data from RTOG 0525, the investigators evaluated a tumor classification that combined tumor biomarkers with the clinical RPA classes. They first identified 4 molecular biomarkers using a training set of 220 archived GBM tumors. The developed molecular predictor was then combined with RPA classification to develop a molecular-clinical predictor (MCP). The median survivals for the combined, 4-class MCP were 65 months, 31 months, 13 months, and 9 months. When the MCP was applied to 725 samples from the RTOG-0525 cohort, it was found that the median survival for the best group had not been reached and it was 26, 16, and 11 months, respectively for the other three groups—validating the result obtained in the training set. The MCP classifier is being used for stratification on future trials and may identify patients requiring intensive treatments beyond the standard of care.
Transcript
Winter 2012 In This Issue:
American Society of Hematology (ASH), American Society for Therapeutic Radiation Onocology (ASTRO), San Antonio Breast Cancer Symposium (SABCS), Radiological Society of North America (RSNA), International Society of Pediatric Oncology (SIOP), Society for Neuro Onocology (SNO) and Others Cooperative Group Abstracts:
Breast Cancer
CNS Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Hematological Cancer
Kidney Cancer
Leukemia, Myelodysplasia, and Transplantation
Lung Cancer
Lymphoma and Plasma Cell Disorders
Melanoma/Skin Cancers
Sarcoma/Bone and Soft Tissue Cancers
Other Cancer NCI/CTEP Abstracts & Activities: DCTD/DCP Abstracts
DCTD and DCP Activities
The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.
Research Highlights in this Issue: POG-9906: A research team from the Children’s Oncology Group ALL Committee, working with collaborators at St. Jude Children’s Research Hospital and the British Columbia Cancer Agency, identified therapeutically targetable novel chromosomal rearrangements and sequence mutations in a subset of patients with high-risk B-precursor ALL. This patient subset was defined by a gene expression profile similar to BCR-ABL1-positive ALL (Ph-like ALL) and showed an increased risk for treatment failure compared to other patients designated as high-risk based on standard clinical factors. Each of the Ph-like ALL cases had genomic alterations resulting in dysregulation of cytokine receptor and kinase signaling. Many of these genomic alterations are targetable with FDA-approved agents (e.g., translocations involving kinases PDGFRB, JAK2, and ABL), providing a clear pathway for clinical translation and for improving outcome for this subset of children with ALL and high risk for treatment failure. The research is a component of the NCI Childhood Cancer TARGET Initiative. RTOG-0525: Molecular classification of cancers is beginning to have impact on the clinical trial designs as demonstrated by the article highlighted in this issue. Using data from RTOG 0525, a large phase 3 clinical trial that enrolled over 700 patients with glioblastoma multiforme (GBM), the investigators were able to validate a combined molecular-clinical classifier. Prognostic classification of GBM has been clinical thus far; one example being Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) based classes. Using the data from RTOG 0525, the investigators evaluated a tumor classification that combined tumor biomarkers with the clinical RPA classes. They first identified 4 molecular biomarkers using a training set of 220 archived GBM tumors. The developed molecular predictor was then combined with RPA classification to develop a molecular-clinical predictor (MCP). The median survivals for the combined, 4-class MCP were 65 months, 31 months, 13 months, and 9 months. When the MCP was applied to 725 samples from the RTOG-0525 cohort, it was found that the median survival for the best group had not been reached and it was 26, 16, and 11 months, respectively for the other three groups—validating the result obtained in the training set. The MCP classifier is being used for stratification on future trials and may identify patients requiring intensive treatments beyond the standard of care.
NCI-Sponsored Groups Meetings Report 2 of 30 Winter 2012
Cooperative Group Abstracts
Breast Cancer
ACRIN Barr RG, Zhang Z, Cormack J, Yeh M, Mendelson EB, Berg WA: Probably Benign Lesions on Screening Breast Ultrasound: Prevalence and Risk of Malignancy in the ACRIN 6666 Trial. Radiological Society of North America (RSNA), Chicago, IL, Nov 2011. Abst. SSA01-02. http://rsna2011.rsna.org/search/event_display.cfm?am_id=2&em_id=11002116&printmode=Y&autoprint=N
Protocol(s): ACRIN-6666 Berg WA, Mendelson EB, LePetross H, Zhang Z, Marques H, Adams A: Reasons for Failed Cancer Detection in the ACRIN 6666 Screening Protocol: Mammography, US, MRI. Radiological Society of North America (RSNA), Chicago, IL, Nov 2011. Abst. SSA01-03. http://rsna2011.rsna.org/search/event_display.cfm?am_id=2&em_id=11006596&printmode=Y&autoprint=N
Protocol(s): ACRIN-6666 Hylton NM, Partridge SC, Rosen M, Kim E, L'Heureux DZ, Esseman L: ACRIN 6698 MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: A Sub-Study of the I-SPY 2 TRIAL (Investigation of Serial Studies To Predict Your Therapeutic Response with Imaging And moLecular Analysis). Cancer Res 2011; 71(24 Suppl): Abst. OT2-03-06. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): ACRIN-6698 Jolles PJ, Kostakoglu L, Bear HD, Idowu MO, Kurdziel K, Shankar L, Mankoff DA, Duan F, L'Heureux DZ: ACRIN 6688 Phase II Study of Fluorine-18 3'-Deoxy-3' Fluorothymidine (FLT) in Invasive Breast Cancer. Cancer Res 2011; 71(24 Suppl): Abst. OT2-05-03. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): ACRIN-6688 Tromberg BJ, L'Heureux DZ, Mankoff DA, Zhang Z, Cerussi A, Mehta R, Carpenter PM, Butler JA, Hylton NM, Kaufman P, Pogue BW, Paulsen K, Yodh AG, Boas D, Isakoff S: ACRIN 6691 Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI). Cancer Res 2011; 71(24 Suppl): Abst. OT2-05-02. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): ACRIN-6688 CALGB Magbanua MM, Sosa EV, Eisenbud LE, Scott J, Olshen A, Pinkel D, Rugo HS, Park JW: Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2011; 29(Suppl 27): Abst. 9. http://meeting.ascopubs.org/cgi/content/short/29/27_suppl/9?rss=1
Other Participant(s): CTSU Protocol(s): CALGB-40502
NCI-Sponsored Groups Meetings Report 3 of 30 Winter 2012
ECOG Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W: A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194. Cancer Res 2011; 71(24 Suppl): Abst. S4-6. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): NCCTG, OTHER Protocol(s): E5194 Wagner LI, Zhao F, Chapman JW, Cella D, Shepherd LE, Sledge GW, Goss PE: Patient-reported predictors of early treatment discontinuation: NCIC JMA.27/E1Z03 quality of life study of postmenopausal women with primary breast cancer randomized to exemestane or anastrozole. Cancer Res 2011; 71(24 Suppl): Abst. S6-2. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): CTSU, NCIC Clinical Trials Group Protocol(s): E1Z03 NCCTG Cheng H, Rimm DL, Reinholz MM, Lingle WL, Ballman KV, Dueck AC, Chen B, McCullough AE, Jenkins RB, Perez EA: Quantitative measurement of antigen degradation in NCCTG N9831 tissue microarrays. Cancer Res 2011; 71(24 Suppl): Abst. PD05-04. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER, SWOG Protocol(s): N9831 Crozier JA, Moreno-Aspitia A, Ballman KV, Martino S, Kutteh LA, Davidson NE, Kaufman PA, Perez EA: Correlation between BMI and clinical outcome of patients with early stage HER2 + breast cancer from the N9831 clinical trial. Cancer Res 2011; 71(24 Suppl): Abst. P2-12-02. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG Protocol(s): N9831 Moreno-Aspitia A, Rowland KM, Liu H, Hillman DW, Stella PJ, Perez EA: Phase II trial of Brostallicin and Cisplatin in patients with metastatic triple negative breast cancer. Cancer Res 2011; 71(24 Suppl): Abst. OT3-01-14. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER, SWOG Protocol(s): N9831 Perez EA, Ballman KV, Reinholz MM, Dueck AC, Cheng H, Jenkins RB, McCullough AE, Chen B, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Geiger XJ, Ingle JN, Tenner KS, Harris LN, Gralow JR, Rimm DL: Impact of quantitative measurement of HER2, HER3, HER4, EGFR, ER and PTEN protein expression of benefit to adjuvant Trastuzumab in early-stage HER2+ breast cancer patients in NCCTG N9831. Cancer Res 2011; 71(24 Suppl): Abst. PD05-03 I. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
NCI-Sponsored Groups Meetings Report 4 of 30 Winter 2012
NCIC Clinical Trials Group Dong B, Chapman J-AW, Yerushalmi R, Goss PE, Pollak MN, Burnell MJ, Bramwell VH, Levine MN, Pritchard KI, Whelan TJ, Ingle JN, Parulekar W, Shepherd LE, Gelmon KA: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. Cancer Res 2011; 71(24 Suppl): Abst. P5-14-01. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): NCIC-MA.21, NCIC-MA.27 Moy B, Shepherd LE, Chapman J-AW, Le Maître A, Gelmon KA, Elliott C, Ingle JN, Goss PE: NCIC CTG MA.27: Clinical Tolerability and Overall Survival of Racial and Ethnic Minority Women on Aromatase Inhibitor Therapy. Cancer Res 2011; 71(24 Suppl): Abst. P2-14-02. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): NCIC-MA.27 NSABP Bear HD, Tang G, Rastogi P, Geyer CE, André R, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Pajon ER, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. Cancer Res 2011; 71(24 Suppl): Abst. PD07-08. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): NSABP-B-40 Fehrenbacher L, Jeong J-H, Rastogi P, Geyer CE, Paik S, Ganz PA, Land SR, Costantino JP, Swain SM, Mamounas EP, Wolmark N: NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. Cancer Res 2011; 71(24 Suppl): Abst. OT1-02-07. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): NSABP-B-47 Julian TB, Anderson SJ, Cobleigh MA, Siziopikou KP, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Chu L, Leasure NC, Atkins JN, Polikoff J, Seay TE, McCaskill-Stevens W, Rabinovitch R, Wolmark N: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2-Positive DCIS Resected by Lumpectomy: NSABP B-43. Cancer Res 2011; 71(24 Suppl): Abst. OT1-02-05. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
NCI-Sponsored Groups Meetings Report 5 of 30 Winter 2012
Julian TB, Costantino JP, Vicini FA, White JR, Cecchini RS, Winter KA, Arthur DW, Kuske R, Rabinovitch R, Parda DS, Mamounas EP, Curran, Jr WJ, Wolmark N: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413. Cancer Res 2011; 71(24 Suppl): Abst. OT2-06-02. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): RTOG Protocol(s): NSABP-B-39, RTOG-0413 Julian TB, Costantino JP, Vicini FA, White JR, Winter KA, Arthur DW, Kuske RR, Rabinovitch R, Curran WJ Jr, Wolmark N: Early Toxicity Results with 3-D Conformal External Beam Therapy (CEBT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S7): Abst. 12. http://www.redjournal.org/article/S0360-3016%2811%2900835-2/fulltext
Other Participant(s): RTOG Protocol(s): NSABP-B-39, RTOG-0413 Julian TB, Vicini FA, Costantino JP, Arthur DW, Kidwell KM, Land SR, Mamounas EP, Wolmark N: Boost Radiation Therapy Not of Value in Reducing IBTR of Invasive or Noninvasive Breast Cancers for Patients with DCIS: Results from the NSABP B-24 Trial. Cancer Res 2011; 71(24 Suppl): Abst. P3-13-01. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): NSABP-B-24 Mamounas EP, Anderson SJ, Julian TB, Krag DN, Weaver DL, Ashikaga T, Harlow SP, Wolmark N: Effect of serial sectioning and immunohistochemistry (IHC) on sentinel lymph nodes (SLNs) on the false-negative rate (FNR) of SLN biopsy (SLNB): Results from NSABP B-32. J Clin Oncol 2011; 29(Suppl 27): Abst. 86. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=111&abstractID=86581
Protocol(s): NSABP-B-32 Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. Cancer Res 2011; 71(24 Suppl): Abst. S2-3. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): CTSU Protocol(s): NSABP-B-34 Shen K, Tang G, Kim C, Pogue-Geile K, Anderson SJ, Constantino JP, Bear HD, Song N, Tian C, Gabrin MJ, Zhang Y, Geyer, Jr CE, Wolmark N: A Genomic Predictor Developed from Breast Cancer Cell Lines Predicts Both Disease-Free Survival and Overall Survival in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide: A Collaborative Project of the NSABP and Precision Therapeutics. Cancer Res 2011; 71(24 Suppl): Abst. P1-06-15. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
NCI-Sponsored Groups Meetings Report 6 of 30 Winter 2012
SWOG Gonzalez-Angulo AM, Barlow WE, Gralow JR, Meric-BernstamF, Hayes DF, Moinpour CM, Ramsey SD, Schott AF, Sparks DB, Albain KS, Hortobagyi GN: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients (pts) with 1-3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007. Cancer Res 2011; 71(24 Suppl): Abst. OT1-03-01. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): CTSU Protocol(s): S1007 Hershman DL, Unger JM, Crew KD, Moinpour CM, Minasian LM, Hansen L, Lew DL, Kaberle K, Wade JL, Meyskens FL: SWOG S0927: A Randomized Double Blind Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor (AI)-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer. Cancer Res 2011; 71(24 Suppl): Abst. OT2-07-02. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Protocol(s): S0927 Mehta RS, Barlow WE, Albain KS, Vandenberg T, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226. Cancer Res 2011; 71(24 Suppl): Abst. S1-1. http://sabcs.org/UserPortal/Documents/Abstract_Book_SABCS_20111215.pdf
Other Participant(s): CTSU Protocol(s): S0226
CNS Cancer
COG Barredo J, Hastings C, Lu X, Marcus R, Winick N, Devidas M, Whitlock J, Richey AK, Hunger S, Carroll W: Inferior Outcome with Reduced Dose Cranial Radiation (12 GY) in Isolated CNS Relapse of All Treated with Intensive Systemic Chemotherapy: A Children’s Oncology Group Study. Pediatr Blood Cancer 2011; 57(5): Abst. O098. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
Protocol(s): AALL02P2 Sands S, Kolva E, Tagliareni L, Salsberg D, Allen J: Baseline Neuropsychological Function and Quality of Life in Newly Diagnosed Primary CNS Germinoma: Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy. Pediatr Blood Cancer 2011; 57(5): Abst. Pub033. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
NCI-Sponsored Groups Meetings Report 7 of 30 Winter 2012
NCCTG Galanis E, Anderson SK, Lafky JM, Kaufmann TJ, Uhm JH, Giannini C, Kumar SK, Northfelt DW, Flynn PJ, Jaeckle KA, Buckner JC: NCCTG Phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (rGBM). Neuro-Onocology 2011; 13(Suppl 3): Abst. NO-93. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii41.abstract
Protocol(s): N0776 Jaeckle KA, Anderson SK, Kosel ML, Sarkaria J, Brown P, Flynn P, Buckner JC, Galanis E: Phase II trial of Imatinib Mesylate; (Gleevec; ST1571) in the treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. A North Central Cancer Treatment Group Study. Neuro-Onocology 2011; 13(Suppl 3): Abst. OT-16. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii85.abstract
Protocol(s): N0272 Kaufmann TJ, Anderson SK, Jaeckle KA, Uhm JH, Northfelt DW, Flynn PJ, Buckner JC, Galanis E: Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging. Neuro-Onocology 2011; 13(Suppl 3): Abst. RA-12. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii136.abstract
Protocol(s): N0776 RTOG Aldape K, Gilbert M, Cahill D, Wang M, Won M, Hegi M, Colman H, Mehta M, Sulman E: Clinical Utility of G-CIMP and IDH1 Status as Dual Prognostic Markers in Glioblastoma. Neuro-Onocology 2011; 13(Suppl 3): Abst. OM-35. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii76.abstract
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Armstrong T, Wang M, Gilbert M, Wefel J, Won M, Bottomley A, Mendoza T, Coens C, Werner-Wasik M, Brachman D, Choucair A, Mehta M: Clinical Utility of Quality of Life (QOL) and Symptom Assessment as Prognostic Factors for Survival and Measures of Treatment Effects on RTOG 0525. Neuro-Onocology 2011; 13(Suppl 3): Abst. QL-3. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii121.abstract
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Brachman D, Wang M, Ashby L, Thomas T, Dunbar E, Rockhill J, Khuntia D, Bovi J, Macher M, Mehta M: Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S129-S130): Abst. 261. http://www.redjournal.org/article/S0360-3016(11)01088-1/fulltext
NCI-Sponsored Groups Meetings Report 8 of 30 Winter 2012
Camphausen K, Wang M, Corn B, Muanza T, Howard S, Mahadevan A, Schultz C, Haas M, Mehta M: Predictive Value of Tumor Recurrence Using Urinary VEGF Levels in Patients Receiving Radiation Therapy for Glioblastoma. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S181): Abst. 1052. http://www.redjournal.org/article/S0360-3016%2811%2901143-6/fulltext
Protocol(s): RTOG-0611 Gilbert M, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle K, Brown P, Armstrong T, Wefel J, Blumenthal D, Mahajan A, Schultz C, Erridge S, Chakravarti A, Curran W, Mehta M: RTOG 0525: A Randomized Phase III Trial Comparing Standard Adjuvant Temozolomide (TMZ) With a Dose-Dense (dd) Schedule in Newly Diagnosed Glioblastoma (GBM). Neuro-Onocology 2011; 13(Suppl 3): Abst. NO-46. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii41.abstract
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Lassman A, Wang M, Gilbert M, Aldape K, Beumer J, Wright J, Takebe N, Puduvallim V, Hormigo A, Gaur R, Werner-Wasik M, Mehta M: Phase II trial of dasatinib in target selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Onocology 2011; 13(Suppl 3): Abst. NO-102. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii41.abstract
Protocol(s): RTOG-0627 Mehta M, Wang M, Aldape K, Stupp R, Jaeckle K, Blumenthal D, Brown P, Erridge S, Curran W, Gilbert M: RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM). Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S128-S129): Abst. 259. http://www.redjournal.org/article/S0360-3016(11)01086-8/fulltext
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Minesh M, Wang M, Aldape K, Gilbert M, Stupp R, Curran W, Sulman E, Jaeckle K, Blumenthal D: Clinical, Molecular, and Molecular-Clinical Profile (MCP) Exploratory Subset Analysis of RTOG 0525: A Phase III trial comparing standard (std) adjuvant Temozolomide (TMZ) with a dose-dense (dd) schedule for Glioblastoma (GBM). European Multidisciplinary Cancer Congress, Stockholm, Sweden, Sep 2011. http://stockholm2011.ecco-org.eu/News-and-alerts/~/media/ECCO%20documents/Stockholm%202011/News%20and%20alerts/Congress%20update%20services/Issue7_August2011_rev3.ashx
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Ratai E, Zhang Z, Snyder B, Girardi V, Gilbert MR, Sorensen AG: Magnetic resonance spectroscopy of anti-VEGF therapy in glioblastoma (GBM): ACRIN 6677 / RTOG 0625. Radiological Society of North America (RSNA), Chicago, IL, Nov 2011. Abst. MSVN31-03. http://rsna2011.rsna.org/search/event_display.cfm?am_id=2&em_id=11004947&printmode=Y&autoprint=N
Other Participant(s): ACRIN Protocol(s): RTOG-0625
NCI-Sponsored Groups Meetings Report 9 of 30 Winter 2012
Ratai E, Zhang Z, Snyder B, Yeh M, Gilbert M, Sorensen AG: Magnetic Resonance Spectroscopy of anti-VEGF therapy in glioblastoma (GBM): ACRIN 6677 / RTOG 0625. American College of Radiology Imaging Network (ACRIN) Annual Meeting, Arlington, VA, Sep 2011. Other Participant(s): ACRIN Protocol(s): RTOG-0625 Sulman E, Cahill D, Wang M, Won M, Hegi M, Mehta M, Aldape K, Gilbert M: A Combined Molecular Clinical Predictor of Survival Validated with the RTOG-0525 Cohort. Neuro-Onocology 2011; 13(Suppl 3): Abst. OM-30. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii76.abstract
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Vogelbaum M, Wang M, Hadjipanayis C, Won M, Mehta M, Gilbert M: The Relationship Between Extent of Resection and Outcome in Newly Diagnosed GBM: Results from RTOG 0525. Neuro-Onocology 2011; 13(Suppl 3): Abst. ST-41. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii154.abstract
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Wang M, Dignam J, Won M, Curran W, Mehta M, Gilbert M: Variation over time and inter-dependence between disease progression and death among patients with Glioblastoma(GBM) on RTOG 0525. Neuro-Onocology 2011; 13(Suppl 3): Abst. EP-11. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii26.abstract
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525 Wefel J, Armstrong R, Wang M, Won M, Bottomley A, Mendoza T, Coens C, Werner-Wasik M, Brachman D, Choucair A, Gilbert M: Clinical Utility of Neurocognitive Function as a Prognostic Factor for Survival and Measure of Differential Between-Arm Treatment Effects on RTOG 0525. Neuro-Onocology 2011; 13(Suppl 3): Abst. NC-05. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii73.abstract
Other Participant(s): NCCTG, OTHER Protocol(s): RTOG-0525
Gastrointestinal Cancer
CALGB Mahmoud NN, Lopatin M, Lee M, Clark-Langone K, Niedzwiecki D, Venook AP: Endpoints for validation of tumor markers for recurrence risk: Recurrence-free interval (RFI), diseasefree survival (DFS), overall survival (OS), and colon-cancer specific survival (CCSS) in CALGB 9581. ECCO16-ESMO36-ESTRO30, Stockholm, Sweden, Sep 2011. Abst. 1411. http://www.ecco-org.eu/ecco_content/ECCO16_AbstractBook/files/assets/seo/page200.html
NCI-Sponsored Groups Meetings Report 10 of 30 Winter 2012
Mahmoud NN, Lopatin M, Lee M, Clark-Langone K, Niedzwiecki D, Venook AP: Endpoints for validation of tumor markers for recurrence risk: Recurrence-free interval (RFI), diseasefree survival (DFS), overall survival (OS), and colon-cancer specific survival (CCSS) in CALGB 9581. European Society for Medical Oncology 2011 Meeting, Stockholm, Sweden, Sep 2011. Abst. 1411. http://new.ecco-org.eu/ecco_content/2011StockholmAbstractbook/files/assets/seo/page200.html
Protocol(s): CR-95-036 RTOG Garofalo M, Moughan J, Hong T, Bendell J, Berger A, Lerma F, Lee R, Anne P, Sharma N, Crane C: RTOG 0822: A Phase II Study of Preoperative (PREOP) Chemoradiotherapy (CRT) Utilizing IMRT in Combination With Capecitabine (C) and Oxaliplatin (O) for Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S3-S4): Abst. 6. http://www.redjournal.org/article/S0360-3016%2811%2900829-7/fulltext
Protocol(s): RTOG-0822 Gunderson L, Moughan J, Ajani J, Pedersen J, Benson A, Thomas C, Mayer R, Haddock M, Rich T, Willett C: Long-term Update of U.S. GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Concurrent Chemoradiation with 5-FU-mytomycin Yields Better Disease-free and Overall Survival than 5-FU-Cisplatin. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S5-S6): Abst. 9. http://www.redjournal.org/article/S0360-3016%2811%2900832-7/fulltext
Other Participant(s): ECOG, NCCTG, NCIC Clinical Trials Group, SWOG Protocol(s): RTOG-98-11 Kachnic L, Winter K, Meropol N, Anne P, Wong S, Watson J, Mitchell E, Pollock J, Lee R, Willett C: Longitudinal Quality of Life (QoL) and Patient-Reported Bowel Function in RTOG 0247. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S98): Abst. 196. http://www.redjournal.org/article/S0360-3016(11)01021-2/fulltext
Protocol(s): RTOG-0247 Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols R, Yalavartihi S, Hayostek C, Willett C: 5-Year Updated Results of RTOG-0012 Randomized Phase II Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S95): Abst. 190. http://www.redjournal.org/article/S0360-3016(11)01015-7/fulltext
Protocol(s): RTOG-R-0012 SWOG Baker LH, Rankin CJ, Blanke CD, Demetri GD, Crowley JJ, Benjamin RS, Stevenson JG, Blackstein ME, Priebat DA, Tap WD, Von Mehren M: Long-term follow-up of SWOG S0033, a Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with un-resectable or metastatic gastrointestinal stromal tumors (GIST). Combined Meeting of Connective Tissue Oncology Society and Musculoskeletal Tumor Society, Chicago, IL, Oct 2011. Paper #24. http://www.ctos.org/meeting/2011/program.pdf
NCI-Sponsored Groups Meetings Report 11 of 30 Winter 2012
Blanke CD, Rankin CJ, Benjamin RS, Raymond AK, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC, Demetri GD, Baker LH: Long-term survival on S0033: a Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs). European Society for Medical Oncology 2011 Meeting, Stockholm, Sweden, Sep 2011. Abst. 9404. http://new.ecco-org.eu/ecco_content/2011StockholmAbstractbook/index.html#/692/zoomed
RTOG Bosch W, Paulus R, Michalski J, Galvin J, Followill D, Bice W, Prestidge B, Sandler H, Hagan M: Analysis of Brachytherapy Plans for Regulatory Compliance: Dosimetric Study of RTOG 0232 Plans to Quantify Expected Dose to Organs at Risk. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S379): Abst. 2354. http://www.redjournal.org/article/S0360-3016(11)01424-6/fulltext
Other Participant(s): CTSU Protocol(s): RTOG-0232 Bruner D, Hunt D, Michalski J, Bosch W, Yan Y, Galvin J, Bahary J, Morton G, Parliament M, Sandler H: Preliminary Analysis of 3DCRT vs. IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: Patient Reported Outcomes. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S44): Abst. 87. http://www.redjournal.org/article/S0360-3016(11)00910-2/fulltext
Protocol(s): RTOG-0126 Chakravarti A, James J, Efstathiou J, Wu C, Klimowicz A, Sandler H, Lautenschlaeger T, Tester W, Hagan M, Shipley W: Bladder Preservation Therapy for Muscle-Invading Bladder Cancers (MIBC): Long-term Clinical Outcomes from RTOG 8802, 8903, 9506, and 9706 and Molecular Correlates along the VEGF Pathway. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S12): Abst. 22. http://www.redjournal.org/article/S0360-3016%2811%2900845-5/fulltext
Other Participant(s): OTHER Protocol(s): RTOG-88-02, RTOG-89-03, RTOG-95-06, RTOG-97-06 Efstathiou J, Paulus R, Smith M, Jones C, Leibenhaut M, Husain S, Rotman M, Souhami L, Sandler H, Shipley W: Cardiovascular Mortality Following Short-Term Androgen Deprivation In Clinically Localized Prostate Cancer: An Analysis Of RTOG 94-08. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S41): Abst. 82. http://www.redjournal.org/article/S0360-3016(11)00905-9/fulltext
Other Participant(s): OTHER Protocol(s): RTOG-94-08 Hamstra D, Dignam J, Porter A, Hanks G, Lawton C, Roach M, Sandler H: Surrogate End-Points for Prostate Cancer Specific Survival: Superiority of the Interval to Biochemical Failure: An Analysis of RTOG 9202 and 9413. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S103): Abst. 205. http://www.redjournal.org/article/S0360-3016(11)01031-5/fulltext
NCI-Sponsored Groups Meetings Report 12 of 30 Winter 2012
Hsu I, Hunt D, Straube W, Pouliot J, Cunha J, Krishnamurthy D, Sandler H: Dosimetric Parameters of Prostate HDR Brachytherapy in Radiation Therapy Oncology Group 0321. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S13-S14): Abst. 25. http://www.redjournal.org/article/S0360-3016(11)00848-0/fulltext
Protocol(s): RTOG-0321 Michalski J, Yan Y, Bruner D, Bosch W, Winter K, Galvin J, Bahary J, Morton G, Parliament M, Sandler H: Preliminary Analysis of RTOG 0126 High Dose Arm Prostate Patients Receiving 3DCRT or IMRT: Toxicity Report. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S1-S2): Abst. 2. http://www.redjournal.org/article/S0360-3016(11)00825-X/fulltext
Protocol(s): RTOG-0126 Movsas B, Hunt D, Bruner D, Lee W, Tharpe H, Goldstein D, Shah A, Dayes I, Parise S, Sandler H: Electronic Web-Based Technology Significantly Improves Quality of Life (QOL) Data Collection: Analysis of RTOG 0828. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S111): Abst. 221. http://www.redjournal.org/article/S0360-3016(11)01047-9/fulltext
Protocol(s): RTOG-0828 Ritter M, Yan Y, Verhoven B, Khor L-Y, Hammond M, Jones C, Amin M, Bahary J, Zeitzer K, Pollock A: Ki-67 Staining Is a Strong Predictor of Patient Outcome for Prostate Cancer Patients Treated on RTOG 94-08. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S11-S12): Abst. 21. http://www.redjournal.org/article/S0360-3016(11)00844-3/fulltext
Other Participant(s): OTHER Protocol(s): RTOG-94-08
Gynecologic Cancer
ECOG Atri, M, Zhang Z, Marques H, Gorelick J, Harisinghani M, Sohaib A, Koh DM, Raman S, Gee M, Choi H, Landrum L, Manne R, Chuang L, Yu J, McCourt C: ACRIN 6671/GOG 0233: Ferumoxtran-10 MRI Review Results. American College of Radiology Imaging Network (ACRIN) Annual Meeting, Arlington, VA, Sep 2011. http://www.acrin.org/Portals/0/Researchers/Meetings%20and%20Awards/Presentations/2011%20Presentations/Atri%20-%20ACRIN%206671%20Presentation.ppt
Other Participant(s): ACRIN Protocol(s): GOG-0233 NCIC Clinical Trials Group Tinker A, Mackay H, Ellard S, Welch S, Eisenhauer E: Preliminary Activity of Temsirolimus, an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix: a NCIC-CTG Phase II Clinical Trial. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, Nov 2011. Abst. C69. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=80af9d1d-b638-476d-883a-1deef5e92bda&cKey=68a01075-e51e-4708-adb8-6ad2351a77f2&mKey=%7bA57FF86D-D414-4079-BCBD-157746574F37%7d
NCI-Sponsored Groups Meetings Report 13 of 30 Winter 2012
RTOG Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, Souhami L, Small W, Gaffney D: Efficacy And Safety of IMRT After Surgery in Patients With Endometrial Cancer: RTOG 0418 Phase II Study. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S45): Abst. 89. http://www.redjournal.org/article/S0360-3016%2811%2900912-6/fulltext
Protocol(s): RTOG-0418 Portelance L, Moughan J, Jhingran A, Miller B, Salehpour M, D'Souza D, Haddock M, Rotman M, Gaffney D: A Phase II Multi-institutional Study of Postoperative Pelvic Intensity Modulated Radiation Therapy (IMRT) with Weekly Cisplatin in Patients with Cervical Carcinoma: Two Year Efficacy Results of the RTOG 0418. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S3): Abst. 5. http://www.redjournal.org/article/S0360-3016(11)00828-5/fulltext
Protocol(s): RTOG-0418
Head and Neck Cancer
RTOG Xiao C, Hanlon A, Zhang Q, Rosenthal D, Nguyen-Tan P, Kim H, Movsas B, Watkins Bruner D: Predictors on Longitudinal Changes of Symptom Clusters Identified in Patients With Head and Neck Cancer Treated on RTOG Trials. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S534): Abst. 2675. http://www.redjournal.org/article/S0360-3016(11)01651-8/fulltext
Protocol(s): RTOG-0129
Hematological Cancer
ECOG Harvey R, Jacobus SJ, Rajkumar S, Greipp PR, Lonial S: Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1882. http://ash.confex.com/ash/2011/webprogram/Paper45134.html
Protocol(s): E4A03 Weiss M, Jacobus SJ, Wagner LI, Cella D, Katz MS, Rajkumar S, Fonseca R: Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 4184. http://ash.confex.com/ash/2011/webprogram/Paper45102.html
NCI-Sponsored Groups Meetings Report 14 of 30 Winter 2012
SWOG Heuck C, Sexton R, Dhodapkar M, Zhang Q, Usmani S, Nair B, Van Rhee F, Hoering A, Crowley J, Shaughnessy JD, Orlowski RZ, Barlogie B: SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3955. http://ash.confex.com/ash/2011/webprogram/Paper45002.html
Protocol(s): S0120 Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Mattar BI, Safah HF, Holmberg L, Dean RM, Orlowski RZ, Barlogie B: Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2004. http://ash.confex.com/ash/2011/webprogram/Paper36877.html
Protocol(s): S0115
Kidney Cancer
SWOG Ryan CW, Tangen CM, Heath EI, Lara PN, Palapattu GS, Mack PC, Stein MN, Ely BW, Thompson IM: SWOG 0931 – Everest: EVErolimus for renal cancer ensuing surgical therapy, a Phase II study. International Kidney Cancer Symposium, Chicago, IL, Oct 2011. http://registeruo.niu.edu/iebms/wbe/wbe_p1_main.aspx?oc=40&cc=WBE4011723
Protocol(s): S0931
Leukemia, Myelodysplasia, and Transplantation
CALGB Edwards CG, Maharry KS, Mrozek KA, Schwind S, Paschka P, Nicolet DR, Kohlschmidt J, Prior TW, Wu Y, Kolitz JE, Blum WG, Pettenati MJ, Dal Cin PS, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD: Cytogenetic, molecular and clinical features associated with rare CBFB-MYH11 fusion transcripts in patients (Pts) with acute myeloid leukemia (AML) and inv(16)/t(16;16). American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2514. http://ash.confex.com/ash/2011/webprogram/Paper39254.html
Protocol(s): CALGB-10503, CALGB-19808, CALGB-9621 Jones JA, Stark A, Zhao WJ, Lin TS, Rai KR, Marcucci G, Peterson B, Larson RA, Heerema NA, Byrd JC: Alemtuzumab consolidation does not improve outcome for CL patients with high risk genomic features on successive CALGB trials. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1791. http://ash.confex.com/ash/2011/webprogram/Paper44166.html
NCI-Sponsored Groups Meetings Report 15 of 30 Winter 2012
Koval GE, Wetzler M, Owzar K, Bloomfield CD, Malnassy GL, Sher DA, Larson RA, Stock W: Abl kinase domain mutations leading to relapse of Ph+ acute lymphoblastic leukemia (ALL) occur commonly and can be detected at initial diagnosis: Molecular results from CALGB 10001. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2541. http://ash.confex.com/ash/2011/webprogram/Paper44386.html
Other Participant(s): SWOG Protocol(s): CALGB-10001 Mendler JH, Maharry KS, Radmacher MD, Mrozek KA, Kohlschmidt J, Nicolet DR, Becker H, Metzeler K, Schwind S, Whitman SP, Blum WG, Powell BL, Kolitz JE, Carter TH, Wetzler M, Moore JO, Carroll AJ, Baer MR, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: Poor outcome of RUNX1-mutated (RUNX1-mut) patients (pts) with primary, cytogenetically normal acute myeloid leukemia (CN-AML) not receiving allogeneic stem cell transplantation (AlloSCT) in first complete remission (CR1) and associated gene- and MicroRNA (miR) expression signatures. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3454. http://ash.confex.com/ash/2011/webprogram/Paper39247.html
Protocol(s): CALGB-10201, CALGB-19808, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9720 Metzeler K, Becker H, Maharry KS, Radmacher MD, Kohlschmidt J, Mrozek KA, Nicolet DR, Whitman SP, Wu Y, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal (CN-) Acute Myeloid Leukemia (AML) within the European Leukemianet (ELN) ‘favorable’ genetic category: A Cancer and Leukemia Group B study. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 417. http://ash.confex.com/ash/2011/webprogram/Paper35959.html
Protocol(s): CALGB-20202, CALGB-8461, CALGB-9665 Mrozek KA, Marcucci G, Maharry KS, Nicolet DR, Becker H, Whitman SP, Metzeler K, Schwind S, Wu Y, Kohlschmidt J, Pettenati MJ, Koduru P, Heerema NA, Block AM, Patil SR, Baer MR, Kolitz JE, Moore JO, Carroll AJ, Larson RA, Bloomfield CD: Prognostic utility of the European LeukemiaNet (ELN) genetic-risk classification predicts outcome of adults with de novo acute myeloid leukemia (AML): A study of 1,550 patients (pts). American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 414. http://ash.confex.com/ash/2011/webprogram/Paper36840.html
Protocol(s): CALGB-10201, CALGB-19808, CALGB-20202, CALGB-8461, CALGB-8525, CALGB-8923, CALGB-9420, CALGB-9621, CALGB-9665, CALGB-9720 Powell BL, Moser BK, Stock W, Gallagher R, Willman C, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum F, Tallman M, Larson RA: Adding mercaptopurine and methotrexate to alternate week ATRA maintenance therapy does not improve the outcome for adults with acute promyelocytic leukemia (APL) in first remission: Results from North American Leukemia Intergroup Trial C9710. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 258. http://ash.confex.com/ash/2011/webprogram/Paper41127.html
NCI-Sponsored Groups Meetings Report 16 of 30 Winter 2012
Woyach J, Ruppert AS, Rai KR, Lin TS, Appelbaum F, Tallman M, Belch A, Larson RA, Byrd JC: Impact of age on outcomes following initial therapy with various chemotherapy and chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia (CLL): Results of CALGB studies. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 289. http://ash.confex.com/ash/2011/webprogram/Paper43135.html
Protocol(s): CALGB-10101, CALGB-9011, CALGB-9712 COG Aplenc R, Fisher BT, Sung L, Keren R, Alonzo TA, Hall M, Huang Y-SV, Li Y, Luan X, Gerbing RB, Bertoch D, Seif AE, Adamson PC, Gamis AS: Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2617. http://ash.confex.com/ash/2011/webprogram/Paper42948.html
Protocol(s): AAML0531 Bhatla T, Morrison DJ, Wang J, Raetz EA, Burke M, Brown P, Carroll WL: Epigenetic Modulation Leads to Re-Expression of Relapse Specific Silenced Genes and Induces Chemosensitivity in Childhood Acute Lymphoblastic Leukemia (ALL). American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3455. http://ash.confex.com/ash/2011/webprogram/Paper39298.html
Protocol(s): Multiple Trials Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer W, Nachman J, Carroll AJ, Heerema NA, Gastier-Foster JM, Willman CL, Linda SB, Winick N, Hunger S, Carroll WL, Larsen EC: Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1440. http://ash.confex.com/ash/2011/webprogram/Paper36984.html
Protocol(s): AALL0232 Coenen E, Raimondi S, Harbott J, Zimmermann M, Alonzo T, Auvrignon A, Beverloo B, Chang M, Creutzig U, Dworzak M, Forestier E, Gibson B, Hasle H, Harrison C, Heerema N, Kaspers G, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Reinhardt D, Rubnitz J, Smith F, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan M, van den Heuvel-Eibrink M: Prognostic Significance of Additional Cytogenetic Aberrations in 733 de novo Pediatric 11q23/MLL-rearranged AML Patients: Results of an International Study. Pediatr Blood Cancer 2011; 57(5): Abst. PB007. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
Protocol(s): Multiple Trials Goldman S, Smith L, Perkins S, Shiramizu B, Gross T, Sanger W, Harrison L, Cairo M: Outcome and Pharmacokinetic (PK) Analysis of Adding Rituximab to FAB Chemotherapy in Children and Adolescents with Advanced Mature B-NHL/Leukemia: A Children’s Oncology Group Report. Pediatr Blood Cancer 2011; 57(5): Abst. O122. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
NCI-Sponsored Groups Meetings Report 17 of 30 Winter 2012
Heerema NA, Raetz EA, Carroll AJ, Borowitz MJ, Devidas M, Gastier-Foster JM, Larsen EC, Loh ML, Mattano LA, Maloney KW, Willman CL, Wood BL, Winick N, Hunger SP, Carroll WL: iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 739. http://ash.confex.com/ash/2011/webprogram/Paper42083.html
Protocol(s): AALL0232, AALL0331 Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch BA, Raimondi SC, Gamis AS, Meshinchi S: The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG). American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1444. http://ash.confex.com/ash/2011/webprogram/Paper42202.html
Protocol(s): POG-9421 Kaeding AJ, Magoon D, Fraiman Y, Jones T, Heerema NA, Carroll AJ, Rao KW, Hilden JM, Hunger SP, Small D, Brown PA: MLL Rearrangement and Age At Diagnosis Are Strongly Associated with High Level Surface FLT3 Expression and Ex Vivo Sensitivity to FLT3 Inhibition: A Prospective Analysis of 54 Consecutive Infants with ALL Enrolled in Children's Oncology Group (COG) Trial AALL0631. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 568. http://ash.confex.com/ash/2011/webprogram/Paper43906.html
Protocol(s): AALL0631 Kutny MA, Alonzo TA, Gerbing RB, Geraghty D, Gamis AS, Lange B, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Meshinchi S: TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 569. http://ash.confex.com/ash/2011/webprogram/Paper37732.html
Protocol(s): AAML03P1, CCG-2961 Lacayo NJ, Alonzo TA, Gayko U, Westfall M, Purvis N, Putta S, Hackett J, Cohen AC, Gerbing RB, Dahl GV, Gamis AS, Meshinchi S: Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3544. http://ash.confex.com/ash/2011/webprogram/Paper41465.html
Protocol(s): POG-9421 Lamba J, Mortland LJ, Mitra A, Walter RB, Pollard JA, Alonzo TA, Gerbing RB, Hirsch BA, Raimondi SC, Franklin J, Meshinchi S: Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3489. http://ash.confex.com/ash/2011/webprogram/Paper40245.html
NCI-Sponsored Groups Meetings Report 18 of 30 Winter 2012
Larsen EC, Salzer W, Nachman J, Devidas M, Freyer DR, Raetz EA, Winick N, Hunger SP, Carroll WL: Treatment Toxicity in Adolescents and Young Adult (AYA) Patients Compared with Younger Patients Treated for High Risk B-Precursor Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group Study AALL0232. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1510. http://ash.confex.com/ash/2011/webprogram/Paper44153.html
Protocol(s): AALL0232 Loh ML, Harvey RC, Mullighan CG, Linda SB, Devidas M, Borowitz MJ, Carroll AJ, Chen IM, Gastier-Foster JM, Heerema NA, Kang H, Raetz EA, Roberts KG, Zhang J, Winick N, Wood BL, Larsen EC, Carroll WL, Willman CL, Hunger SP: BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 743. http://ash.confex.com/ash/2011/webprogram/Paper40262.html
Protocol(s): AALL0232 Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, Davies SM, Smith FO, Gamis AS, Meshinchi S: Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status - Comparison of Morphology and Multidimensional Flow Cytometry: A Report From the Children's Oncology Group AML Protocol AAML0531. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 939. http://ash.confex.com/ash/2011/webprogram/Paper41743.html
Protocol(s): AAML0531 Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, Davies SM, Smith FO, Gamis AS, Meshinchi S: Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse - a Report From the Children's Oncology Group. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3545. http://ash.confex.com/ash/2011/webprogram/Paper41469.html
Protocol(s): AAML0531 Mangum DS, Shams S, Downie JM, von Schwedler U, Rodic V, Engel M, Barnette P, Frazer JK, Trede N, Pei D, Cheng C, Pui C, Hunger SP, Yang JJ, Miles RR, Mullighan CG, Schiffman JD: Focal 22q11.22 Loss Combined with IKZF1 Alterations Predict Very Poor Outcome in Childhood Acute Lymphoblastic Leukemia. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 741. http://ash.confex.com/ash/2011/webprogram/Paper37681.html
Protocol(s): POG-9906 Maude SL, Tasian SK, Vincent T, Hall JW, Collins-Underwood R, Mullighan CG, Hunger SP, Willman CL, Loh ML, Grupp SA, Teachey DT: Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 249. http://ash.confex.com/ash/2011/webprogram/Paper39016.html
NCI-Sponsored Groups Meetings Report 19 of 30 Winter 2012
Moore AS, Alonzo TA, Gerbing RB, Lange B, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S: The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3555. http://ash.confex.com/ash/2011/webprogram/Paper42939.html
Protocol(s): AAML03P1, CCG-2961 Orgel E, Sposto R, Malvar J, Seibel NL, Ladas EJ, Gaynon P, Freyer DR: Extremes of Weight Are Associated with Increased Treatment-Related Toxicity in High-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3574. http://ash.confex.com/ash/2011/webprogram/Paper42229.html
Protocol(s): CCG-1961 Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, Raetz EA, Gardner S, Gastier-Foster JM, Howrie D, Goyal R, James D, Borowitz MJ, Barnes YJ, Patil SR, Teachey DT, Taylor C, Grupp SA: A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children'sOncology Group Study ASCT0431. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 837. http://ash.confex.com/ash/2011/webprogram/Paper41563.html
Protocol(s): ASCT0431 Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Whitlock JA, Adamson PC, Hunger SP, Carroll WL: Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 573. http://ash.confex.com/ash/2011/webprogram/Paper39033.html
Protocol(s): ADVL04P2 Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange B, Tweardy DJ, Meshinchi S: FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 938. http://ash.confex.com/ash/2011/webprogram/Paper40928.html
Protocol(s): CCG-2961 Roberts KG, Morin RD, Zhang J, Hirst M, Harvey RC, Kasap C, Chen X, Edmonson M, Chen IM, Shah N, Devidas M, Reaman GH, Smith MA, Pui C-H, Downing JR, Gerhard DS, Willman CL, Loh ML, Hunger SP, Marra MA, Mullighan CG: Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 67. http://ash.confex.com/ash/2011/webprogram/Paper40205.html
NCI-Sponsored Groups Meetings Report 20 of 30 Winter 2012
Ross JA, Linabery AM, Blommer C, Langer E, Spector LG, Hilden JM, Heerema NA, Tower RL, II, Davies SM: Genetic Susceptibility Loci and Risk of Infant Leukemia by Subtype and MLL status: A Children's Oncology Group Report. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 749. http://ash.confex.com/ash/2011/webprogram/Paper36164.html
Protocol(s): Multiple Trials ECOG Cesano A, Putta S, Mathi K, Rosen D, Gayko U, Hawtin R, Cripe LD, Sun Z, Tallman MS, Paietta EM: Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2512. http://ash.confex.com/ash/2011/webprogram/Paper38346.html
Protocol(s): E3993, E3999 Douer D, Zickl L, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd LE, Willman CL, Bloomfield CD, Rowe JM, Wiernik PH, Tallman MS: Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 83. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/83?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=douer&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Other Participant(s): CALGB, NCIC Clinical Trials Group, SWOG Protocol(s): E2491 Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS: Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3619. http://ash.confex.com/ash/2011/webprogram/Paper44769.html
Protocol(s): E1900 Figueroa ME, Malinge S, Chion T, Li Y, Paietta EM, Fernandez HF, Tallman MS, Weiss MJ, Chou ST, Melnick AM, Crispino J: Development of Acute Megakaryoblastic Leukemia in Down Syndrome Is Associated with Sequential Epigenetic Changes That Target the Down Syndrome Critical Region on Chromosome 21. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3451. http://ash.confex.com/ash/2011/webprogram/Paper38966.html
Protocol(s): E1900 Foran JM, Sun Z, Fernandez HF, Cripe LD, Ketterling RP, Racevskis J, Luger SM, Paietta EM, Lazarus HM, Litzow MR, Tallman MS: The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2568. http://ash.confex.com/ash/2011/webprogram/Paper38139.html
NCI-Sponsored Groups Meetings Report 21 of 30 Winter 2012
Van Vlierberghe P, Ambesi A, Rigo I, Paietta EM, Racevskis J, Wiernik PH, Rowe JM, Rue M, Ferrando AA: ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 406. http://ash.confex.com/ash/2011/webprogram/Paper41523.html
Protocol(s): INT-0132 SWOG Advani AS, Gundacker H, Nyatanga N, Elson P, Rosen PJ, Bates J, Sekeres MA, Kalaycio M, Sobecks R, Copelan E, Appelbaum FR: Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2594. http://ash.confex.com/ash/2011/webprogram/Paper38362.html
Protocol(s): SWOG-9030 Advani AS, Gundacker H, Slovak ML, Theil KS, Forman SJ, Radich JP, Appelbaum FR: Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2555. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/2555?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=gundacker&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Protocol(s): S0333, SWOG-9400 Ho PA, Othus M, Ostronoff F, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S: Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3516. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3516?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=othus&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Protocol(s): SWOG-9031, SWOG-9333, SWOG-9500 Newell LF, Othus M, Walter RB, Petersdorf SH, Chauncey T, Anderson JE, Godwin JE, Kopecky KJ, Appelbaum FR, Estey EH: Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1446. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/1446?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=newell&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Protocol(s): S0106, S0112, S9918, SWOG-9031, SWOG-9333 Ostronoff F, Othus M, Ho PA, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S: KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2150. http://ash.confex.com/ash/2011/webprogram/Paper38013.html
Protocol(s): SWOG-9031, SWOG-9333 Ostronoff F, Othus M, Ho PA, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S: DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3519. http://ash.confex.com/ash/2011/webprogram/Paper38003.html
NCI-Sponsored Groups Meetings Report 22 of 30 Winter 2012
Pogosova-Agadjanyan EL, Kopecky KJ, Petersdorf SP, Erba HP, Stone RM, Meshinchi S, Nevill TJ, Radich JP, Stenke L, Slovak ML, Stuart RK, Tallman MS, Willman CL, Mortensen RM, Wentz BL, Appelbaum FR, Stirewalt DL: Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2520. http://ash.confex.com/ash/2011/webprogram/Paper40030.html
Protocol(s): S0106
Lung Cancer
ACRIN Black W: Cost-Effectiveness of Screening in the National Lung Screening Trial (NLST) ACRIN 6654. American College of Radiology Imaging Network (ACRIN) Annual Meeting, Arlington, VA, Sep 2011. Protocol(s): ACRIN-6654 Gareen I: Smoking Cessation Behavior in the National Lung Screening Trial (NLST) ACRIN 6654. American College of Radiology Imaging Network (ACRIN) Annual Meeting, Arlington, VA, Sep 2011. Protocol(s): ACRIN-6654 Machtay M, Duan F, Gorelick J, Snyder B, Edelman MJ, Siegel B, Mahon I, Bradley J, Chiles C: Is there an Optimal Concurrent chemo-RT regimen for Stage III NSCLC? -- Preliminary analysis of ACRIN 6668/RTOG 0235. Journal of Thoracic Oncology 2011; 6(Suppl 2): Abst. O23.05. https://www.webges.com/cslide/library/wclc/mylibrary/search/session//354_120
Other Participant(s): RTOG Protocol(s): ACRIN-6668 Machtay M, Duan F, Snyder B, Gorelick J, DeNittis A, Chiles C, Mahon I, Alavi A, Bradley J, Siegel BA: Relationship of Tumor Metabolic Activity on FDG-PET and Survival after Treatment for Stage IIB/III NSCLC: Preliminary Results from ACRIN 6668/RTOG 0235. Radiological Society of North America (RSNA), Chicago, IL, Nov 2011. Abst. MSVC31-12. http://rsna2011.rsna.org/search/event_display.cfm?am_id=2&em_id=11010227&printmode=Y&autoprint=N
Protocol(s): ACRIN-6668 Machtay M, Duan F, Snyder B, Gorelick J, DeNittis AS, Chiles C, Mahon I, Alavi A, Bradley J, Siegel B: Can Tumor FDG-PET Scan Uptake (SUV) Predict Local Control in Stage III NSCLC? Preliminary Results from ACRIN 6668/RTOG 0235. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S134-S135): Abst. 271. http://www.redjournal.org/article/S0360-3016%2811%2901098-4/fulltext
Other Participant(s): RTOG Protocol(s): ACRIN-6668
NCI-Sponsored Groups Meetings Report 23 of 30 Winter 2012
Machtay M, Duan F, Snyder B, Gorelick J, Edelman M, Bradley J, DeNittis A, Siegel B, Mahon I, Chiles C, Alavi A: Local Control Outcomes in Stage III NSCLC: Report from ACRIN 6668/RTOG 0235. American College of Radiology Imaging Network (ACRIN) Annual Meeting, Arlington, VA, Sep 2011. Other Participant(s): RTOG Protocol(s): ACRIN-6668 CALGB Janne PA, Wang X, Socinski MA, Crawford J, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke RA, Vokes EE, Miller VA: Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406. Journal of Thoracic Oncology 2011; 6(6; Suppl 2): Abst. O39.01. https://www.webges.com/cslide/library/wclc/mylibrary/search/session//354_148
Protocol(s): CALGB-30406 Lamont EB, He Y, Lan L, Joffe S: Clinical trial efficacy vs. real world effectiveness of cisplatin and etoposide in the care of elderly Medicare patients with extensive stage small cell lung cancer. International Society for Geriatric Onocology, Paris, France, Nov 2011. Paper Session 2. http://www.siog.org/images/SIOG_documents/paris_2011_final_program.pdf
Protocol(s): CALGB-70802 ECOG Sandler AB, Byrtek M, Fages S, Schiller JH, Dowlati A, Brahmer JR, Johnson DH: Clinical patterns and outcomes for the bevacizumab maintenance population in the ECOG E4599 study of patients with advanced non-small cell lung cancer (NSCLC): results of an exploratory analysis. World Conference on Lung Cancer, Amsterdam, The Netherlands, Jul 2011. Abst. P3.216. http://abstracts.webges.com/myitinerary/author.html
Other Participant(s): CTSU Protocol(s): E4599 Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano SL, Leighl NB, Adjei A, Schiller JH: Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E1505, a Phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer. World Conference on Lung Cancer, Amsterdam, The Netherlands, Jul 2011. Abst. 2278. http://abstracts.webges.com/myitinerary/author-87.html
Other Participant(s): CTSU, SWOG Protocol(s): E1505
NCI-Sponsored Groups Meetings Report 24 of 30 Winter 2012
RTOG Bradley J, Paulus R, Komaki R, Masters G, Forster K, Schild S, Bogart J, Garces Y, Narayan S, Choy H: A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-dose (74 Gy) Conformal Chemoradiotherapy +/- Cetuximab for Stage IIIA/IIIB Non-Small Cell Lung Cancer: Preliminary Findings on Radiation Dose in RTOG 0617 [late-breaking abstract]. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl): Abst. [Late-breaking abstract]. http://www.redjournal.org/webfiles/images/journals/rob/Late%20Breaking%20Abstracts.pdf.
Other Participant(s): CTSU Protocol(s): RTOG-0617 Edelman M, Paulus R, Suntharalingam M, Krasna M, Burrows W, Gore E, Yom S, Choy H: RTOG 0229:A Phase II Trial of Concurrent Chemotherapy and Full Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy For Locally Advanced Non Small Cell Carcinoma of the Lung. Journal of Thoracic Oncology 2011; 6(6; Suppl 2): Abst. O23.02. https://www.webges.com/cslide/library/wclc/mylibrary/search/session//354_120
Protocol(s): RTOG 0229 Gondi V, Paulus R, Bruner D, Meyers C, Gore E, Wolfson A, Werner-Wasik M, Choy H, Movsas B: Decline in Tested and Patient-reported Cognitive Functioning Following Prophylactic Cranial Irradiation for Lung Cancer: Secondary Analysis of RTOG 0212 and 0214. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S50): Abst. 98. http://www.redjournal.org/article/S0360-3016(11)00921-7/fulltext
Other Participant(s): CALGB, CTSU, ECOG, SWOG Protocol(s): RTOG-0212, RTOG-0214 Komaki R, Paulus R, Ettinger D, Videtic G, Bradley J, Glisson B, Choy H: Final Results of a Phase II Study of Accelerated High Dose Thoracic Radiation Therapy (AHTRT) With Concurrent Chemotherapy for Limited Small Cell Lung Cancer: RTOG 0239. Journal of Thoracic Oncology 2011; 6(6; Suppl 2 S640-S641): Abst. MO19.02. https://www.webges.com/cslide/library/wclc/mylibrary/search/session//354_176?page=2
Protocol(s): RTOG-0239 Kong F, Machtay M, Videtic G, Loo B, Gore E, Wagner H, Varlotto J, Faria S, Dilling T, Sun A: Using During-RT PET to Individualize Adaptive RT for Patients With Stage III NSCLC: A RTOG Planning Study. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S603): Abst. 2818. http://www.redjournal.org/article/S0360-3016(11)01954-7/fulltex
Other Participant(s): ACRIN Protocol(s): RTOG-1106 Li J, Galvin J, Harrison A, Timmerman R, Yu Y, Xiao Y: Dosimetric Verification Using Monte Carlo Calculations for Tissue Heterogeneity-corrected Conformal Treatment Plans for Lung Cancer Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S854): Abst. 3349. http://www.redjournal.org/article/S0360-3016(11)02338-8/fulltext
NCI-Sponsored Groups Meetings Report 25 of 30 Winter 2012
Xiao Y, Cui Y, Kong F, Appenzoller L, Beatty R, Maxim P, Ritter T, Sohn J, Higgins J, Galvin J: Establishment of a Pre-Clinical Trial Process for Dosimetric Feasibility Study of Adaptive Radiotherapy for Patients with Stage III NSCLC. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S613): Abst. 2840. http://www.redjournal.org/article/S0360-3016%2811%2901976-6/fulltext
Other Participant(s): ACRIN Protocol(s): RTOG-1106
Lymphoma and Plasma Cell Disorders
CALGB Kostakoglu L, Schöder H, Hall NC, Straus DJ, Johnson JL, Schwartz L, LaCasce AS, Jung S, Bartlett NL, Canellos GP, Cheson BD: Interim FDG PET imaging in stage I/II non-bulky Hodgkin lymphoma: Would using combined PET and CT criteria better predict response than each test alone? American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3644. http://ash.confex.com/ash/2011/webprogram/Paper38577.html
Protocol(s): CALGB-50203 COG Cairo MS, Day N, Goldman S, Sanger WG, Harrison L, Lim MS, Miles RR, Perkins SL: Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children's Oncology Group Report. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1587. http://ash.confex.com/ash/2011/webprogram/Paper37370.html
Protocol(s): ANHL01P1 Fernandez KS, Chen L, Schwartz C, Chauvenet AR, de Alarcon PA: Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols: A Report From the Children's Oncology Group. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 91. http://ash.confex.com/ash/2011/webprogram/Paper40223.html
Protocol(s): POG-9425, POG-9426 Goldman S, Galardy PJ, Smith L, Perkins SL, Shiramizu B, Gross T, Sanger WG, Harrison L, Cairo MS: Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 2702. http://ash.confex.com/ash/2011/webprogram/Paper37387.html
Protocol(s): ANHL01P1 Schwartz C, Chen L, Constine L, Wolden S, Keller FG, Kelly KM, Friedman Dl: The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 3649. http://ash.confex.com/ash/2011/webprogram/Paper42325.html
NCI-Sponsored Groups Meetings Report 26 of 30 Winter 2012
Schwartz C, Friedman D, McCarten K, Wolden S, Voss S, Constine L, Chen L: Early PET and CT as Predictors of Outcome in Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer 2011; 57(5): Abst. O071. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
Protocol(s): AHOD0031 ECOG Advani RH, Hong F, Gordon LI, Gascoyne RD, Wagner H, Hoppe RT, Fisher RI, Bartlett NL, Kahl BS, Stiff PJ, Cheson BD, Belch AR, Friedberg JW, Kassis J, Blum KA, Habermann TM, Tuscano JM, Horning SJ: Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 1603. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/1603?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=stiff&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Other Participant(s): CALGB, NCIC Clinical Trials Group, SWOG Protocol(s): E2496 Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Horning SJ: Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. LBA-6. http://ash.confex.com/ash/2011/webprogram/Paper45422.html
Protocol(s): E4402 Scott DW, Chan FC, Hong F, Rojic S, Tan K, Meissner B, Farinha P, Horning SJ, Fisher RI, Bartlett NL, Shepherd LE, Connors JM, de Sousa AB, Kahl BS, Gordon LI, Steidl C, Gascoyne RD: A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 430. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/430?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=farinha&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Other Participant(s): CALGB, NCIC Clinical Trials Group, SWOG Protocol(s): E2496 Winter JN, Hong F, Rimsza L, LeBlanc M, Variakojis D, Krajewska M, Habermann TM, Melnick AM, Weick JW, Pollock F, Botros I, Reed JC, Fisher RI, Horning SJ, Kahl BS, Gascoyne RD: Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 87. http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/87?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=melnick&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Other Participant(s): CALGB, SWOG Protocol(s): E4494
NCI-Sponsored Groups Meetings Report 27 of 30 Winter 2012
NCIC Clinical Trials Group Meyer RM, Gosopodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar R, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen B, Shepherd LE: Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 590. http://ash.confex.com/ash/2011/webprogram/Paper38019.html
Other Participant(s): ECOG Protocol(s): JHD06 SWOG Press OW, Unger JM, Rimsza LM, Friedberg J, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Maloney DG, Cheson BD, Miller TP, Fisher RI: A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma. American Society of Hematology (ASH), San Diego, CA, Dec 2011. Abst. 98. http://ash.confex.com/ash/2011/webprogram/Paper39037.html
Protocol(s): S0016
Melanoma/Skin Cancers
NCCTG Diekmann BB, Pockaj B, Novotny PJ, Sloan JA: Quality of life (QOL) in patients who present with malignant melanoma undergiong SLN biopsy (CP). International Society for Quality of Life Research (ISOQOL), Denver, Colorado, Oct 2011. http://www.isoqol.org/2011conference/ac11abstractbook.pdf
Protocol(s): Multiple Trials
Other Cancer
COG DuBois S, Shusterman S, Reid J, Ingle A, Ahern C, Baruchel S, Glade-Bender J, Ivy P, Grier H, Adamson P, Blaney S: Tolerability and Pharmacokinetic Profile of Sunitinib Given as a Powder Formulation to Children with Refractory Solid Tumors: A Children’s Oncology Group Study. Pediatr Blood Cancer 2011; 57(5): Abst. O042. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
Protocol(s): ADVL0612 Frazier L, Nicholson J, Olson T, Dang H Krailo M, Millmire D, Thornton C, Hale J: Prognostic Classification of Pediatric Germ Cell Tumors. Pediatr Blood Cancer 2011; 57(5): Abst. O145. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
NCI-Sponsored Groups Meetings Report 28 of 30 Winter 2012
Zils K, Marina N, Bielack S, Jovic G, Pickering J, Sydes MR, Smeland S, Whelan J, Bernstein M: Lack of Centralization and Under-recruiting of Young Adults: Lessons from EURAMOS-1/AOST0331 (NCT00134030). Pediatr Blood Cancer 2011; 57(5): . http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
Protocol(s): AOST0331 NCCTG Bartels M, Goldberg R, Sloan J: Genetics and QOL: How the interface can impact research and practice. International Society for Quality of Life Research (ISOQOL), Denver, Colorado, Oct 2011. http://www.isoqol.org/2011conference/ac11abstractbook.pdf
Protocol(s): Multiple Trials RTOG Cui Y, Galvin J, Parker W, Breen S, Yin F, Papiez L, Li A, Bednarz G, Chen W, Xiao Y: Process and Initial Experience of Remote Credentialing of 3D IGRT Data for Institutions Participating in RTOG Clinical Trials. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S810): Abst. 3257. http://www.redjournal.org/article/S0360-3016(11)02245-0/fulltext
Protocol(s): Multiple Trials Molineau A, Hernandez N, Alvarez P, Ibbott G, Galvin J, Followill D: Results from 1005 IMRT irradiations of an anthropomorphic head and neck phantom. American Association of Physicists in Medicine Annual Meeting, Vancouver, BC, Canada, Jul 2011. Abst. 15529. http://www.aapm.org/meetings/amos2/pdf/59-15529-79373-907.pdf
SWOG Barlow WE: Designing a Randomized Trial to Test an Interaction of Treatment and a Continuous Genomic Assay. International Society for Clinical Biostatistics, Ottawa, Canada, Aug 2011. Abst. 106.3. http://www.iscb2011.info/documents/prelimprog_orals1.pdf
Other Participant(s): CTSU Protocol(s): S1007
Sarcoma/Bone and Soft Tissue Cancers
COG Baruchel S, Pappo A, Krailo M, Baker K.S., Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM: Phase 2 trial of Trabectedin in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, and Nonrhabdomyosarcoma Soft Tissue Sarcomas: A Children’s Oncology Group Study. Pediatr Blood Cancer 2011; 57(5): Abst. PJ014. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
NCI-Sponsored Groups Meetings Report 29 of 30 Winter 2012
Goldsby R, Krailo M, Wagner L, Krasin M, Randall RL, Lee S, Powell CL, Kim G, Gorlick R, Marina N, Vilaluna D, Meyer J: Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma: A Report from the Children’s Oncology Group. Pediatr Blood Cancer 2011; 57(5): Abst. O036. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
Protocol(s): AOST06P1 Wiener A, Nagarajan R, Hjorth L, Jenney M, Bernstein M, Krailo M, Sydes M, Calaminus G: Quality of Life (QOL) in Osteosarcoma: Preliminary Results of the Initial Treatment Period of EURAMOS-1 (NCT00134030). Pediatr Blood Cancer 2011; 57(5): Abst. PD003. http://onlinelibrary.wiley.com/doi/10.1002/pbc.23299/pdf
Protocol(s): AOST0331 RTOG Finkelstein S, Trotti A, Letson G, Russel M, DeLaney T, Alektair K, Michalski J, Wang D, Kadir T, Stevens C: Deformable Imaging Capability for the Radiation Therapy Oncology Group (RTOG) Consensus Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Lower Extremities. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S684-S685): Abst. 2992. http://www.redjournal.org/article/S0360-3016%2811%2901774-3/fulltext
Ryu S, James J, Gerszten P, Yin F, Timmerman R, Hitchcock Y, Movsas B, Kanner A, Berk L, Kachnic L: RTOG 0631 Phase II/III Study of Image-Guided Stereotactic Radiosurgery for Localized Spine Metastases: Phase II Results. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S131-S132): Abst. 265. http://www.redjournal.org/article/S0360-3016(11)01092-3/fulltext
Protocol(s): RTOG-0631 Wang D, Zhang Q, Kirsch D, Okuno S, Kane J, Li X, Roberge D, Finkelstein S, DeLaney T, Eisenberg B: A RTOG Phase II Trial of Image Guided Preoperative Radiotherapy For Primary Soft Tissue Sarcoma of the Extremity: Acute Toxicity Report. Int J Radiat Oncol Biol Phys 2011; 81(2 Suppl S117): Abst. 234. http://www.redjournal.org/article/S0360-3016(11)01060-1/fulltext
Protocol(s): RTOG-0630
NCI/CTEP Abstracts & Activities
Abstracts with DCTD and DCP Investigators
Houghton PJ, Maris JM, Keir ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Kurmasheva RT, Whiteman KR, Smith MA: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, Nov 2011. Abst. C105. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=6c8432c0-f76b-48e4-9436-b705b459795c&cKey=89132cf5-5012-4583-9120-704fb55538b1&mKey={A57FF86D-D414-4079-BCBD-157746574F37}
NCI-Sponsored Groups Meetings Report 30 of 30 Winter 2012
Lock RB, Carol H, Szymanska B, Boehm I, Evans K, Houghton PJ, Smith MA: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, Nov 2011. Abst. C107. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=6c8432c0-f76b-48e4-9436-b705b459795c&cKey=d2482971-73af-4335-96c6-017246bf4d93&mKey={A57FF86D-D414-4079-BCBD-157746574F37}
Mann BS, Yabroff R, Harlan L, Zeruto C, Abrams J: Clinical Management and Survival in the Patterns of Care Study of Patients Diagnosed with Glioblastoma Multiforme and Reported to the Surveillance, Epidemiology, and End Results Program in 2006. Neuro-Onocology 2011; 13(suppl 3): iii26-iii29: Abst. EP-02. http://neuro-oncology.oxfordjournals.org/content/13/suppl_3/iii26.abstract?sid=acf932a4-1fd7-4527-af8e-39761749373f
Reynolds CP, Kang MH, Carol H, Lock RB, Gorlick R, Kolb EA, Alexander D, Kurmasheva RT, Keir ST, Maris JM, Wu J, Houghton PJ, Smith MA: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408). AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, Nov 2011. Abst. C106. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=6c8432c0-f76b-48e4-9436-b705b459795c&cKey=9090c48b-b696-4e71-bb2d-28ef4790557b&mKey={A57FF86D-D414-4079-BCBD-157746574F37}
Smith MA, Kang MH, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, Nov 2011. Abst. C103. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=6c8432c0-f76b-48e4-9436-b705b459795c&cKey=8dfae041-b60d-4fc9-94b8-f417af633036&mKey={A57FF86D-D414-4079-BCBD-157746574F37}
DCTD and DCP Activities
Scientific Mann BS (DCTD/CTEP): Chair of Planning Committee. NIH State of the Science Conference on Role of Active Surveillance in Management of Prostate Cancer, Bethesda, MD, Dec 2011. http://consensus.nih.gov/2011/prostate.htm
Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.
